Fox News Examines 'Wild West' Peptide Craze as FDA Faces Pressure

Fox News published a major feature Thursday examining the surging peptide market, describing it as a “Wild West” as demand for GLP-1 and other peptide therapies outpaces regulatory frameworks. The piece comes as the FDA prepares to evaluate whether to loosen restrictions on several peptides during a meeting this summer.

The article, headlined “Wild West peptide craze surges beyond GLP-1s as FDA faces pressure to ease access,” quotes Dr. Alex Tatem, an Indiana-based board-certified urologist with expertise in men’s health and peptides, who characterized GLP-1 medications as “incredibly effective at what they do” while warning that the compounding pharmacy ecosystem built around them now sits at a crossroads with pharmaceutical giants.

Compounding Meets Demand

Dr. Tatem explained that the national shortage of GLP-1 drugs — including semaglutide and tirzepatide — created a legal pathway for compounding pharmacies to manufacture versions of these medications. That flexibility allowed patients access to smaller, more frequent dosing that commercial single-dose pens could not provide.

“There are patients I can prescribe tirzepatide to and they can do OK with a once-a-week [dose], but they end up developing nausea with that initial injection — and then by the end of the week, they’re hungry again,” Tatem told Fox News.

That compounding flexibility, however, has created what the doctor called a “huge clash” between commercial pharmaceutical companies and compounders. Novo Nordisk, in a statement to Fox News, said it “supports FDA’s recent thorough scientific analysis and conclusion that there is no medical basis or clinical need for the continued mass compounding of unapproved semaglutide and liraglutide drugs.”

source

FDA Summer Review

The FDA is expected to evaluate potential regulatory changes for multiple peptides during a summer 2026 meeting — a development that follows the agency’s April reclassification of 12 peptides, which removed seven of them from Category 2 enforcement discretion. Two months later, the regulatory landscape continues to shift as patient demand, provider interest, and pharmaceutical industry lobbying all intensify.

Tatem noted that some peptides “have been widely administered for more than a decade without major health complications like toxicity or cancer,” yet remain outside the full FDA approval process. In September 2023, the FDA “quietly” tightened regulation of 19 peptides, making them illegal to manufacture in compounding settings.

“They seemed to be working and seemed to be efficacious for patients, and all of a sudden they were banned, which inadvertently ended up contributing to this surge in interest,” Tatem said. “We kind of saw the same thing happen with peptides that we saw with prohibition.”

Wider Media Wave Continues

The Fox News feature is the latest in a sustained wave of mainstream media attention on the peptide space. In recent weeks, Forbes examined the regulatory oversight gap, The Lancet warned the peptide craze was outpacing regulation, and the ABC in Australia reported on a growing illicit peptide trade tied to influencers and athletes.

The pattern is clear: peptides have moved from a niche subculture to a front-page regulatory topic.

The Risk Side

Fox News also highlighted safety concerns. The piece noted that most “trendy” peptides — marketed for injury recovery, skin rejuvenation, sleep improvement, and growth hormone stimulation — remain unavailable by prescription and circulate through gray-market channels.

“These were all medications that were designed to help people live well and live as healthy as possible,” Tatem said. “And in reality, that was also their downfall in the American healthcare system, because if you are going to get a drug approved and to market, it has to treat a disease state.”

The article cited the ECRI and ISMP safety warning on compounded peptides from earlier this month, which flagged that the peptide boom is outpacing available safety data.

What Comes Next

With the FDA summer meeting approaching and public interest continuing to climb, the peptide regulatory debate shows no signs of cooling. The Fox News feature — reaching a national audience of millions — represents both a sign of the topic’s mainstreaming and a pressure point on regulators.

Dr. Tatem summarized the patient perspective: “The desire to function at our highest level is something that we all feel.” Whether regulators, compounders, and pharmaceutical companies can build a framework that serves that desire safely remains the central question.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.